NO984341L - Polysakkarid-peptid-konjugater - Google Patents

Polysakkarid-peptid-konjugater

Info

Publication number
NO984341L
NO984341L NO984341A NO984341A NO984341L NO 984341 L NO984341 L NO 984341L NO 984341 A NO984341 A NO 984341A NO 984341 A NO984341 A NO 984341A NO 984341 L NO984341 L NO 984341L
Authority
NO
Norway
Prior art keywords
polysaccharide
linker
spacer
immunogenic
conjugate
Prior art date
Application number
NO984341A
Other languages
English (en)
Other versions
NO323870B1 (no
NO984341D0 (no
Inventor
Monique Moreau
Noulle Mistretta
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of NO984341D0 publication Critical patent/NO984341D0/no
Publication of NO984341L publication Critical patent/NO984341L/no
Publication of NO323870B1 publication Critical patent/NO323870B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
NO19984341A 1997-01-21 1998-09-18 Fremgangsmate for a konjugere et peptid til et polysakkarid. NO323870B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97100884 1997-01-21
PCT/EP1998/000654 WO1998031393A2 (en) 1997-01-21 1998-01-21 Polysaccharide-peptide-conjugates

Publications (3)

Publication Number Publication Date
NO984341D0 NO984341D0 (no) 1998-09-18
NO984341L true NO984341L (no) 1998-11-11
NO323870B1 NO323870B1 (no) 2007-07-16

Family

ID=8226387

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984341A NO323870B1 (no) 1997-01-21 1998-09-18 Fremgangsmate for a konjugere et peptid til et polysakkarid.

Country Status (14)

Country Link
US (1) US6472506B1 (no)
EP (1) EP0959905B1 (no)
JP (1) JP4290766B2 (no)
KR (1) KR100593466B1 (no)
AT (1) ATE451124T1 (no)
AU (1) AU722315B2 (no)
CA (1) CA2246760C (no)
DE (1) DE69841362D1 (no)
DK (1) DK0959905T3 (no)
ES (1) ES2335557T3 (no)
NO (1) NO323870B1 (no)
NZ (1) NZ331578A (no)
PT (1) PT959905E (no)
WO (1) WO1998031393A2 (no)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040001842A1 (en) * 1997-05-12 2004-01-01 Dov Michaeli Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors
DE19821859A1 (de) * 1998-05-15 1999-12-09 M Alexander Schmidt Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis
DE69934890D1 (de) * 1998-06-16 2007-03-08 Univ Oklahoma Glykosulfopeptide und verfahren zu deren herstellung und deren verwendung
US7223845B2 (en) 1998-06-16 2007-05-29 The Board Of Regents Of The University Of Oklahoma Synthetic glycosulfopeptides and methods of synthesis thereof
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
US7723296B2 (en) * 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
OA12590A (en) * 2001-01-23 2006-06-08 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine.
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2002309706A1 (en) * 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0220198D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Modified saccharides,conjugates thereof and their manufacture
US6695447B1 (en) 2002-09-30 2004-02-24 Eastman Kodak Company Ink jet recording element
US20050118199A1 (en) * 2003-10-07 2005-06-02 Esser Mark T. Process for covalently conjugating polysaccharides to microspheres or biomolecules
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
TWI264608B (en) * 2005-04-08 2006-10-21 Delta Electronics Inc Light tunnel module
DE602006015665D1 (de) * 2005-10-06 2010-09-02 Nestec Sa Probiotische enterokokken für eine verbesserte immunität
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
SI2457920T1 (en) 2007-01-18 2018-02-28 Genzyme Corporation Oligosaccharides containing the amino acid group and their conjugates
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
JP2009242372A (ja) * 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
WO2010014909A1 (en) * 2008-08-01 2010-02-04 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
CA3040973A1 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates
DK2430151T3 (da) 2009-05-14 2014-09-15 Sanofi Pasteur Meningokokvaccine på basis af lipooligosaccharid (los) fra modificerede stammer af neisseria meningitidis med immuntype l6
WO2010130896A2 (fr) 2009-05-14 2010-11-18 Sanofi Pasteur Procédé pour adjuver le lipopolysaccharide (lps) des bactéries à gram-négatif
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2013082149A1 (en) * 2011-11-28 2013-06-06 Case Western Reserve University Polysaccharide therapeutic conjugates
US10471118B2 (en) 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
US11129845B2 (en) 2014-06-18 2021-09-28 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US10925980B2 (en) 2014-08-04 2021-02-23 Case Western Reserve University Molecular probes and methods of use
US11407786B2 (en) 2015-06-18 2022-08-09 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12060318B2 (en) 2015-10-09 2024-08-13 Case Western Reserve University Compositions and methods for the delivery of nucleic acids
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
EP0326111A3 (en) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
CA2047033A1 (en) * 1990-07-19 1992-01-20 Elizabeth E. Sugg Cyclic hiv principal neutralizing determinant peptides

Also Published As

Publication number Publication date
DK0959905T3 (da) 2010-04-06
US6472506B1 (en) 2002-10-29
ATE451124T1 (de) 2009-12-15
CA2246760C (en) 2012-01-10
WO1998031393A3 (en) 1998-09-11
NO323870B1 (no) 2007-07-16
CA2246760A1 (en) 1998-07-23
DE69841362D1 (de) 2010-01-21
EP0959905B1 (en) 2009-12-09
NO984341D0 (no) 1998-09-18
AU6295798A (en) 1998-08-07
EP0959905A2 (en) 1999-12-01
WO1998031393A2 (en) 1998-07-23
KR20000064696A (ko) 2000-11-06
AU722315B2 (en) 2000-07-27
JP2000507974A (ja) 2000-06-27
PT959905E (pt) 2010-02-05
NZ331578A (en) 2000-05-26
KR100593466B1 (ko) 2007-04-25
JP4290766B2 (ja) 2009-07-08
ES2335557T3 (es) 2010-03-29

Similar Documents

Publication Publication Date Title
ATE451124T1 (de) Polysaccharid-peptid-konjugate
IL135148A0 (en) A polysaccharide conjugate and pharmaceutical compositions containing the same
ATE238064T1 (de) Verbesserte meningokokken polysaccharid-konjugat vakzine
TR200001615T2 (tr) Polietilen Glikol-Grf konjugatlarının yere-özel hazırlanması.
WO2006116475A3 (en) Immunostimulatory compositions
YU6297A (sh) Farmaceutski preparati za imunomodulaciju
DK1019089T3 (da) Langtidsvirkende lægemidler og farmaceutiske præparater der omfatter disse
IS2608B (is) Bóluefnissamsetning sem samanstendur af mótefnisvaka og peptíði sem hefur ónæmisglæðandi eiginleika.
WO2001051510A3 (en) G-csf conjugates
CA2283868A1 (en) Photosensitizer conjugates for pathogen targeting
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
EP0830456A4 (en) INSULATED FrpB NUCLEIC ACID MOLECULE AND CORRESPONDING VACCINE
WO1998019697A3 (en) Novel pharmaceutical compositions
CA2324467A1 (en) Formulations for protection of peg-interferon alpha conjugates
DE69317435D1 (de) Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
ATE313796T1 (de) Konjugate definierter stöchiometrie
TW332816B (en) Peptide and carbohydrate
RU93057952A (ru) Биологический активный макромолекулярный конъюгат, гидразинсодержащие конъюгаты полипептидов и гликополипептидов с полимерами

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees